Comparative Pharmacology
Head-to-head clinical analysis: GASTROGRAFIN versus UROVIST CYSTO PEDIATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GASTROGRAFIN versus UROVIST CYSTO PEDIATRIC.
GASTROGRAFIN vs UROVIST CYSTO PEDIATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gastrografin is a water-soluble iodinated contrast agent that increases the radiodensity of the gastrointestinal tract, allowing visualization on X-ray. It acts by absorbing X-rays due to its high iodine content.
Radiopaque contrast agent that provides enhanced visualization of the urinary tract by attenuating X-rays due to its iodine content.
Oral or rectal: 50-100 mL of a 1:1 dilution with water (or full strength as needed) for CT or fluoroscopic studies. Typically single dose.
Not applicable; Urovist Cysto Pediatric is a contrast agent for cystourethrography, instilled intravesically as a single dose of 5-10 mL for infants and 10-30 mL for children, not a systemic drug.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours (for absorbed diatrizoate); prolongation in renal impairment (up to 20 hours in anuria).
After intravesical administration, systemic absorption is minimal; therefore, a meaningful terminal half-life is not defined. If absorbed, the elimination half-life of diatrizoate is approximately 1–2 hours in patients with normal renal function, reflecting rapid renal clearance.
Renal: 80-90% (glomerular filtration, unchanged); Biliary/Fecal: <5% (minor biliary excretion of absorbed fraction).
Urovist Cysto Pediatric (diatrizoate meglumine) is not significantly absorbed systemically after intravesical administration. The small fraction absorbed is excreted unchanged in urine via glomerular filtration, with 95% eliminated within 24 hours after intravenous administration; biliary/fecal excretion is negligible.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent